Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Zimmer Biomet Holdings Inc. Stock Rises 3.4%, Outperforms Market

Zimmer Biomet Holdings Inc. Stock Rises 3.4%, Outperforms Market

Dow JonesDow Jones2026/10/12 20:35

This article was automatically generated by Dow Jones using technology from Automated Insights.

Shares of Zimmer Biomet Holdings Inc. rallied 3.4% to $92.17 on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average rising 0.4% to 51,850.55 and the S&P 500 Index falling 0.1% to 7,807.24.

This was the stock's third consecutive day of gains.

Zimmer Biomet Holdings Inc. closed 13.8% below its 52-week high of $106.88, which the company reached on October 22nd.

The stock demonstrated a mixed performance when compared to some of its peers, as Johnson & Johnson rose 0.9% to $263.73, Medtronic PLC rose 3.9% to $91.93, and Stryker Corp. rose 1.90% to $282.60.

Trading volume totaled 1.8 million, compared to the 50-day average of 2.1 million.

Data source: Dow Jones Market Data, FactSet

(END) Dow Jones Newswires

October 12, 2026 16:35 ET (20:35 GMT)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Why did the Reserve Bank of Australia raise interest rates two weeks ago? Meeting minutes reveal inflation risks have become a reality, and waiting would be too costly

The Reserve Bank of Australia acknowledges that the trade-off between inflation and full employment has worsened, but maintains that its goal is to return the Consumer Price Index (CPI) to the 2-3% target range.

智通财经•2026/10/13 02:41

Three-year remission rate up to 94%! Johnson & Johnson (JNJ.US) Tremfya Crohn's disease study shows positive long-term results

Long-term data from two Phase 3 clinical trials by Johnson & Johnson show that adult Crohn's disease patients treated with Tremfya (guselkumab) achieved a clinical remission rate of up to 94% over three years.

智通财经•2026/10/13 01:56

Kroger (KR.US) faces the largest layoffs in 143 years: cutting one-third of positions, more than 3,000 employees to be let go

Kroger has laid off 3,000 employees, accounting for more than one-third of its total workforce, marking the largest layoff in its 143-year history. The resources saved will be redirected towards price reductions and frontline operations.

智通财经•2026/10/13 01:36